tirzepatide shortage news october 2025 FDA says of GLP-1 is over Food and Drug Administration Reconfirms

To initiate your weight loss journey with Tirzepatide, you can either contact us directly to discuss your options with a specialist or conveniently book an appointment online through our website

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control, facilitate clinically meaningful weight loss, improve survival, and reduce the risk of renal failure and major adverse cardiovascular events

Tirzepatide is administered once weekly, similar to some other injectables, offering both convenience and flexibility for our patients

The FDA recommends using a backup method of contraception for 4 weeks after starting tirzepatide or after each dose increase

As a result, we encourage other nonprofit newsrooms, mission-aligned outlets, and advocacy organizations to republish our original content under the following conditions: 1

Serious but uncommon events reported in trials or post-market include: Pancreatitis Gallbladder disease Acute kidney injury related to: Volume loss Allergic reactions Hypoglycemia can happen when tirzepatide is combined with insulin or certain oral diabetes drugs